Key Highlights: Implications: Vyome is buying its way into a large, fast‑growing immunology market with next‑generation, more selective JAK inhibitors, without overextending its balan...
Key Highlights: Implications: With legal access to the Charpentier CRISPR/Cas9 patents, Aurigene can now run gene‑editing projects (target validation, disease models, f...
Key Highlights: Implications: The expanded BAT2506 deal gives Intas a late‑stage TNF‑α biosimilar in a broad immunology class, reinforcing its biologics presence in rheumatology ...
